Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 36 min ago
Peer-reviewedCC BY-NC-ND 4.0Cell reports

Activation of a Yap1-mesenchymal-like program in β-cells during diabetes

7 affiliations
  1. 1Department of Medicine, Division of Endocrinology, Columbia University, New York, NY, USA
  2. 2Naomi Berrie Diabetes Center, Columbia University, New York, NY, USA
  3. 3Department of Medicine, Division of Digestive Diseases, Emory University, Atlanta, GA, USA
  4. 4Present address: Department of Medicine, Division of Digestive Diseases, Emory University, Atlanta, GA, USA
  5. 5Lead contact
  6. 6Present address: Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Weill Center for Metabolic Health, Weill Cornell Medicine, New York, NY, USA
  7. 7Forkhead BioTherapeutics, Inc., New York, NY, USA

Abstract

SUMMARY: A critical driver of type 2 diabetes is the failure of insulin-secreting β cells due to dysfunction and loss of cell number or identity. The signaling pathways that trigger these events remain unclear. Here, we identify an epithelial-to-mesenchymal (EMT)-like program that is activated in β cells to promote their loss with type 2 diabetes. This program is initiated in human and mouse β cells by the EMT transcription factor Yap1. While this protein is normally not present in β cells, Yap1 becomes upregulated in response to oxidative stress and impaired mitochondrial function. Chemical inhibition of Yap1 in islets reverses EMT-like activation while its overexpression in cells triggered the appearance of mesenchymal-like vimentin+ cells. Functionally, blocking Yap1 in isolated islets and in mice improves insulin secretion and alleviates diabetes. Taken together, we have identified a novel pathway of β-cell failure during type 2 diabetes, revealing a potential target for future diabetes treatment.

Related

  1. Single-cell dissection of shoulder-derived mesenchymal stem cells reveals source-specific progenitor heterogeneity and a SIX2-driven chondrogenic program.
    Jiabao Ju, Pingping Lin, Dingxiao Xue +6
    Cell biology and toxicologyPeer-reviewedCC BY-NC-NDFull textHuman geneticsEurope PMCPMC
  2. Early morphological and gene/protein expression dynamics of human synovial mesenchymal stem cells during adhesion to a damaged meniscal surface
    Tomoko Meguro, Kentaro Endo, Nobutake Ozeki +4
    Scientific ReportsPeer-reviewedCC BYFull textHuman geneticsDOAJ
  3. Gene amplification during differentiation of mesenchymal stem cells towards chondrocytes
    Paula E. Schwarz, Magali Cucchiarini, Shusruto Rishik +3
    Experimental and Therapeutic MedicinePeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMCPMC
  4. Immune Consequences of Endothelial Cells’ Activation and Dysfunction During Sepsis
    Stéphanie Pons, Marine Arnaud, Maud Loiselle +3
    Critical Care ClinicsPeer-reviewedLicence not stated75 citedEpidemiology & public healthHAL
  5. The systemic administration of multipotent mesenchymal stromal cells alters the inflammatory response in the lung during murine polymicrobial sepsis.
    Anna Kanewska, Ina Lackner, Marco Dechant +7
    Cell and tissue researchPeer-reviewedCC BYFull textHuman geneticsEurope PMCPMC
BibTeX
@article{mckimpson2026activation,
  title = {{Activation of a Yap1-mesenchymal-like program in β-cells during diabetes}},
  author = {Wendy M. McKimpson and Nehan Hoque and Matthew Barter and Jinsook Son and April Y. Lee and Hitoshi Watanabe},
  journal = {Cell reports},
  year = {2026},
  month = jun,
  doi = {10.1016/j.celrep.2026.117596},
  url = {https://doi.org/10.1016/j.celrep.2026.117596},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Activation of a Yap1-mesenchymal-like program in β-cells during diabetes
AU  - Wendy M. McKimpson
AU  - Nehan Hoque
AU  - Matthew Barter
AU  - Jinsook Son
AU  - April Y. Lee
AU  - Hitoshi Watanabe
PY  - 2026
DA  - 2026/06/30
JO  - Cell reports
DO  - 10.1016/j.celrep.2026.117596
UR  - https://doi.org/10.1016/j.celrep.2026.117596
AB  - SUMMARY: A critical driver of type 2 diabetes is the failure of insulin-secreting β cells due to dysfunction and loss of cell number or identity. The signaling pathways that trigger these events remain unclear. Here, we identify an epithelial-to-mesenchymal (EMT)-like program that is activated in β cells to promote their loss with type 2 diabetes. This program is initiated in human and mouse β cells by the EMT transcription factor Yap1. While this protein is normally not present in β cells, Yap1 becomes upregulated in response to oxidative stress and impaired mitochondrial function. Chemical inhibition of Yap1 in islets reverses EMT-like activation while its overexpression in cells triggered the appearance of mesenchymal-like vimentin+ cells. Functionally, blocking Yap1 in isolated islets and in mice improves insulin secretion and alleviates diabetes. Taken together, we have identified a novel pathway of β-cell failure during type 2 diabetes, revealing a potential target for future diabetes treatment.
SN  - 2211-1247
ER  -